Axonics Modulation Technologies said today it raised $40.1 million in financing, with $20.1 million coming from an equity offering and $20 million from a new credit facility. The Irvine, Calif.-based company is developing sacral nerve modulation technology designed for treating patients with urinary and bowel dysfunction. The equity financing round was led by Longitude Capital and […]
Axonics Modulation Technologies
5 medtech stories we missed this week: Jan. 26, 2018
From Attune Medical receiving FDA 510(k) clearance to Synapse Medical having CE Mark approval, here are 5 medtech stories we missed this week but thought were still worth mentioning. 1. Attune Medical gets FDA 510(k) clearance Attune Medical announced in a Jan. 8 press release that it has received FDA 510(k) clearance for its EnsoETM […]
Axonics touts first patients treated in sacral neuromod study
Axonics Modulation Technologies said today that the first 11 patients in its Artisan-SNM sacral neuromodulation study have been implanted with the company’s device designed to treat urinary and bowel dysfunction. The patients were implanted at four centers across the US and Western Europe, the Irvine, Calif.-based company said. The trial will look to enroll 120 patients […]
FDA approves Axonics IDE trial for r-SNM neuromod
Axonics Modulation Technologies said today it won FDA investigational device exemption clearance to engage in a pivotal study of its r-SNM rechargeable sacral neuromodulation system designed for treating overactive bladder and bowel dysfunction. The Irvine, Calif.-based company said it expects to begin enrolling patients in the clinical study in November, aiming to enlist 120 patients at […]
Mainstay Medical taps ex-NuVasive COO Hannon for CEO | Personnel Moves, Sept. 7, 2017
Mainstay Medical (EPA:MSTY) said this week that it tapped former NuVasive Inc. (NSDQ:NUVA) president & COO Jason Hannon to succeed Peter Crosby as CEO, effective Oct. 9. Crosby, recruited in 2009 to lead the company and its development of the Reactiv8 neurostimulation device for treating chronic pain, is slated to act as a consultant for Mainstay through […]
Axonics adds $21m to Series C round
Axonics Modulation Technologies said today that it put another $21 million in its coffers in the second tranche of a Series C round for its sacral nerve modulation technology in treating overactive bladder syndrome. The first, $15 million Series C tranche closed in May. The latest, $20.5 million tranche takes Axonics’ total raise to at least $106.1 […]
Axonics raises another $15m for U.S. sacral neurostim trial
Axonics Modulation Technologies said today that it put nearly $15 million into its coffers as it readies a pivotal study later this year for its sacral nerve modulation technology in treating overactive bladder syndrome. The Irvine, Calif.-based company said it hopes to add another $15.5 million to the $14.5 million it pulled in from its Series C […]
Axonics wins Health Canada nod for rechargeable sacral neuromod system
Axonics Modulation Technologies said today it won Health Canada approval for its rechargeable Sacral Neuromodulation System designed to treat overactive bladder, fecal incontinence and urinary retention. The Irvine, Calif.-based company said it expects to be treating patients with the device during the 1st quarter of this year. “The Health Canada approval provides Axonics with another important […]
Axonics launches post-market sacral neuromod OAB study
Axonics Modulation Technologies said today it launched the Relax-OAB 65-patient post-market clinical follow-up study of its SNM system designed to treat overactive bladder. The SNM rechargeable neuromod system is designed to treat overactive bladder, urinary retention and fecal incontinence through sacral nerve stimulation, the Irvine, Calif.-based company said. Axonics touted the 1st implants and enrollments […]
Axonics wins CE Mark for SNM, touts cost-efficacy study
Axonics Modulation Technologies said today it won CE Mark approval in the European Union for its SNM sacral nerve modulation system and announced the publication of a cost-efficacy study of the device in Neurourology and Urodynamics. The SNM rechargeable neuromod system is designed to treat overactive bladder, urinary retention and fecal incontinence through sacral nerve stimulation, […]
Axonics pulls in $39m Series B for neurmod bladder control device
Axonics Modulation Technologies said today it raised $38.5 million in a Series B financing round for its sacral neurmodulation technology. Irvine, Calif.-based Axonics is developing a miniaturized rechargeable neuromod stimulator to treat overactive bladder, urinary retention and fecal incontinence. Proceeds from the round will go towards a clinical study of its neurmod device in treating […]